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http://www.biomedcentral.com/1471-2393/13/2RESEARCH ARTICLE Open AccessPrenatal micronutrient supplementation and
postpartum depressive symptoms in a pregnancy
cohort
Brenda MY Leung1, Bonnie J Kaplan1,2*, Catherine J Field3, Suzanne Tough1,2, Misha Eliasziw1,4,
Mariel Fajer Gomez3, Linda J McCargar3 , Lisa Gagnon5and the APrON Study TeamAbstract
Background: Postpartum depression is a serious problem for women and their offspring. Micronutrient
supplements are recommended for pregnant women because of their documented protective effects for the
offspring, but their potential beneficial effects on maternal mental health are unknown. This study investigated the
association between prenatal micronutrient supplementation and the risk for symptoms of postpartum depression
in a longitudinal pregnancy cohort from the Alberta Pregnancy Outcomes and Nutrition (APrON) study.
Methods: Participants came from a cohort of the first 600 APrON women. Supplemental nutrient intake and
symptoms of depression (measured with the Edinburgh Postnatal Depression Scale (EPDS)) were collected at each
trimester and 12 weeks postpartum.
Results: Of the 475 participants who completed the EPDS at least twice in pregnancy and at 12 weeks postpartum,
416 (88%) scored <10 and 59 (12%) scored ≥10, where an EPDS ≥10 is considered to be “at least probable minor
depression”. Mean nutrient intakes from supplements were higher in women with lower EPDS scores, particularly
selenium (p = 0.0015) and omega-3s (p = 0.01). Bivariate analyses showed that several demographic and social/
lifestyle variables were associated with EPDS ≥10: not having been born in Canada (p = 0.01), greater number of
chronic conditions (p = 0.05), greater number of stressful life events during this pregnancy (p = 0.02), and lower
prenatal and postnatal support (p = 0.0043 and p = 0.0001, respectively). Adjusting for covariates and nutrients
known to be associated with postpartum depression, logistic regression showed that having a prenatal EPDS ≥ 10
increased the odds of postpartum depressive symptoms (second and third trimester OR = 3.29, 95% CI = 1.55 -
7.01, p = 0.004 and OR = 4.26, 95% CI = 2.05 - 8.85, p < 0.0001, respectively), while prenatal supplemental selenium
(per 10 mcg, OR = 0.76, 95% CI = 0.74 - 0.78, p = 0.0019) and postnatal social support (OR = 0.87, 95% CI = 0.78 - 0.97,
p = 0.0015) were protective.
Conclusions: Multiple factors, including supplementary selenium intake, are associated with the risk of postpartum
depressive symptoms. Future research on dietary supplementation in pregnancy with special attention to selenium
intake is warranted.
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Postpartum depression is a serious mental health problem
that has been estimated to affect 10 - 15% of women after
the birth of a child [1], and can occur anywhere from
shortly after birth to one year postpartum. A review by
Gavin and colleagues stated the prevalence may be as high
as 19% within the first three months of giving birth [2].
The difference in rates may be due to the diagnostic
criteria, timing of screening, and screening instruments
used [1]. Regardless of the precise prevalence rate, it is
clear that postpartum depression poses a significant public
health issue because of its impact not only on the lives of
the women themselves, but also on their children’s growth
and development (cognitive, social, behavioural) [3,4].
A number of social and biological factors are known to
be associated with an increased risk for developing
postpartum depression. Social risk factors include a history
of depression/anxiety, lack of a marital partner, marital diffi-
culties, poverty, and lack of social support [5], as well as
family violence, life stress, and substance abuse [6]. Bio-
logical risk factors associated with postpartum depression
include hormonal influences [7] and nutrient deficiencies
from malnutrition or poor diet quality [8-10]. Research has
shown a number of nutrient deficiencies associated with
depression in the non-pregnant or postpartum population,
including folate and vitamin B12 [11,12] , calcium [12,13],
iron [11,12,14], selenium [11,15], zinc [11,16] and omega-3
polyunsaturated fatty acids [11,17-23]. Postpartum depres-
sion is not qualitatively different from depression that is
not linked to pregnancy, but only recently has research on
the role of nutrients in postpartum depression begun to
emerge [24]. A summary has been published elsewhere
describing some of the known biochemical effects of these
nutrients on brain and neurological function, pointing
toward the neurophysiological mechanisms by which
insufficient nutrients could influence mood [24].
It is well-documented that proper nutrition during
pregnancy is vital to the health of a woman and her fetus
[25,26]. Today, it is common for health professionals to
recommend that pregnant women take micronutrient
supplements, the benefits of which have been established
for the offspring. For instance, a meta-analysis by Goh and
colleagues reported that offspring of women who took pre-
natal multivitamins were less likely to have leukemia (odds
ratio (OR)=0.61, 95% confidence interval (CI)=0.50-0.74),
pediatric brain tumors (OR=0.73, 95% CI=0.60-0.88) and
neuroblastoma (OR=0.53, 95% CI=0.42-0.68), compared to
children whose mothers did not take supplements [27]. An-
other meta-analysis found prenatal supplements to be
associated with decreased risk for a number of congenital
anomalies (e.g. cardiovascular defects, limb defects, urinary
tract anomalies, and cleft palate or oral cleft anomalies), in
addition to neural tube defects [28]. A meta-analysis of
research in developing countries showed that multiplemicronutrient supplementation was more effective than
iron and folic acid supplementation at reducing the risk of
low birth weight (RR=0.86, 95% CI=0.79-0.93) and of small
size for gestational age (RR=0.85; 95% CI=0.78-0.93), but
had no effect on perinatal mortality [29].
These results demonstrate important protective effects
for the offspring from maternal use of prenatal multiple
micronutrient supplementation. The effect of prenatal
supplementation on maternal mental health, however,
has not been established. The purpose of this study was
to investigate the association between prenatal micronu-
trient supplementation and the risk for postpartum
depressive symptoms in pregnant women from the Alberta
Pregnancy Outcomes and Nutrition (APrON) study. We
evaluated the nutrients ingested through supplements to
determine whether any individual supplementary
nutrients were associated with postpartum depressive
symptoms as measured by the Edinburgh Postnatal
Depression Scale (EPDS).
Methods
Study design and participants
Participants for this study are the first 600 pregnant women
from the APrON study, which is a longitudinal prospective
study in Alberta, Canada. Participants were at least 16 years
old with gestational age ≤27 weeks. Women must be in the
first (T1) or second (T2) trimester to be in this study; we
did not include any woman who was 28 weeks or beyond.
Non-English speakers, known drug and alcohol abusers,
and those planning to move out of the region within 6
months were excluded. Data were collected using
questionnaires and interviews at each trimester and 12
weeks postpartum. Windows for data collection were
defined a priori as week 10 ±2 for first trimester,
week 18 ± 2 for second trimester, and week 32 ± 2 for
third trimester. Every attempt was made to meet these
specific timepoints as closely as possible (see Figure 1).
Details of recruitment and data collection are avail-
able elsewhere [30]; also refer to the APrON website
at www.ApronStudy.ca.
Participant background and covariates
Data on sociodemographic background and variables such
as stressful life events and perceived social support known
to be associated with increased risk for postpartum de-
pression were collected using a questionnaire developed
specifically for the APrON study (see Table 1). Perceived
social support was measured with questions from the
National Population Health Survey (NPHS) – Social
Support section (Statistics Canada, 1994/95 & 1996/97
cycles) [31] with response options modified for the
APrON study. The NPHS-Social Support section is
comprised of four statements about having “someone to
confide in”, “someone one can count on in a crisis”,
1st Trimester 2nd Trimester 3rd Trimester 3 months 6 1    2 3
(1-13 weeks) (14-26 weeks) (27-42 weeks) post partum months year years       years
Physical Measurements
Maternal nutrient status (blood)
Maternal urine (18 wks)
Anthropometrics
Maternal & Paternal DNA (once)
Physical Measurements
Maternal nutrient status (blood)
Maternal urine
Child DNA 
Maternal and child anthropometrics 
Breast milk 
Questionnaires
Infant health & development
Maternal mental & physical 
health
Infant/child feeding
Maternal diet & activity
Questionnaires
Diet & activity
Mental & physical health
Medical history
Biological fathers
Birth and Delivery 
Record
Planned Measurements
Child neurocognitive battery  
Figure 1 APrON timeline.
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who makes one feel loved and cared for”, with Yes/No
response options. Guided by expert advice from team
members, the APrON study kept the wording of the
statements, but modified the response options to five
possible answers: none of the time, a little of the time,
about half of the time, most of the time, all of the time.
Each response option was then assigned a numerical
value, “none of the time” was assigned a value of 0 and
ranged up to a value of 4 for “all of the time”. By summing
the scores of each statement, an overall score of 16
indicated the highest possible level of perceived social sup-
port, while an overall score of 0 was the lowest possible
level of perceived social support.Prenatal nutrient intake from supplements
The Supplement Intake Questionnaire was developed
for APrON to assess natural health product (NHP)
intake. The structure of the Supplement Intake
Questionnaire was adapted from questionnaires used
in other studies of supplement intake, such as the National
Cancer Institute and the Canadian Community Health
Survey [32,33]. The Supplement Intake Questionnaire
was pilot tested with a panel of nutrition experts as
well as 50 pregnant women to determine whether it
captured NHP data efficiently and accurately. Wording,
formatting, and other modifications were made based on
the feedback from the pilot study.The final version of the Supplement Intake Questionnaire
consisted of three sections: 1) section 1 listed options for
multivitamins/minerals, 2) section 2 listed single nutrient
supplements, and 3) section 3 consisted of herbal products,
probiotics, homeopathic remedies, and other products such
as amino acids, essential fatty acids and traditional
medicines. Commonly used formulations were presented in
a checklist. For products used by participants but not in the
checklist, space was provided to record the name and
manufacturer of the NHP as well as the Natural Product
Number (NPN) or Drug Identification Number (DIN).
Where possible, the products were verified using their
NPNs and DINs against those within Health Canada’s
Natural Health Products Database, to confirm their
formulations; then they were entered into the APrON
database. A NPN or a DIN is assigned to all NHPs
that have met standards for quality, safety and effi-
cacy set by Health Canada [34]. Products that did not
have a NPN or DIN were verified by obtaining ingredients
from product labels or by finding the information from
the manufacturer/supplier websites.
At each visit during pregnancy and postpartum,
women were asked to describe in detail the quantity
(i.e., frequency of intake and dosage) and type (e.g.,
prenatal multivitamins) of NHP consumed, using open-
ended questions. To determine dose, women were asked
“how much do you take?” and for frequency, women were
asked “how often do you take it?” Typical responses were
daily or times per week (e.g., 5 x/week). There was no
Table 1 Associations between socio-demographic characteristics of women and their postpartum EPDS
Characteristic EPDS<10* EPDS≥10* p-value** Odds ratio***(95% CI)
Demographics
Age (mean (95% CI)) 31.2 (30.8 - 31.6) 31.6 (30.3 - 32.8) 0.51 1.0 (0.9 - 1.1)
BMI (mean (95% CI)) 24.1 (23.6 - 24.5) 24.2 (22.9 - 25.4) 0.90 1.0 (0.9 - 1.0)
Marital status (n (%))
Married/common-law 406 (88.0) 55 (11.9) 0.17 1.0
Single/divorced 9 (75.0) 3 (25.0) 2.4 (0.6 - 9.3)
Education (n (%))
High school 36 (87.8) 5 (12.2) 0.96 1.0
Trade/undergrad 286 (87.7) 40 (12.2) 0.6 (0.1 - 7.0)
Graduate 93 (87.7) 13 (12.2) 0.6 (0.1 - 5.9)
Household Income (n (%))
< $20K 5 (83.3) 1 (16.7) 0.13 1.0
$20-$39K 12 (80.0) 3 (20.0) 1.2 (0.1 - 15.1)
$40-$69K 47 (78.3) 13 (21.7) 1.4 (0.1 - 12.9)
$70-$99K 107 (87.7) 15 (12.3) 0.7 (0.1 - 6.4)
≥$100K 236 (90.1) 26 (9.9) 0.5 (0.1 - 4.9)
Born in Canada (n (%))
Yes 349 (89.9) 39 (10.0) 0.01 1.0
No 63 (79.7) 16 (20.2) 2.3 (1.2 - 4.3)
Ethnicity (n (%))
Caucasian 363 (88.3) 48 (11.6) 0.30 1.0
Non-causasian 51 (83.6) 10 (16.4) 1.5 (0.7 - 3.1)
# of children (n (%))
0 57 (87.7) 8 (13.3) 0.28 1.0
1-2 172 (88.2) 23 (11.8) 1.0 (0.5 - 1.9)
3-4 4 (66.7) 2 (34.3) 7.3 (1.0 - 53.7)
Social/lifestyle
# of chronic conditions (n (%))
0 206 (85.1) 36 (14.9) 0.05 1.0
1 91 (91.9) 8 (8.1) 0.5 (0.2 - 1.1)
2 15 (78.9) 4 (21.0) 1.5 (0.5 - 4.8)
3 5 (62.5) 3 (37.5) 3.4 (0.8 – 15.0)
# of life event stresses (n (%))
During this pregnancy
0 207 (89.6) 24 (10.4) 0.02 1.0
1-2 184 (88.0) 25 (11.9) 1.2 (0.6 - 2.1)
>3 24 (72.7) 9 (27.2) 3.2 (1.3 - 7.7)
12 mos before pregnancy
0 196 (89.9) 22 (10.1) 0.08 1.0
1-2 149 (88.2) 20 (11.8) 1.2 (0.6 - 2.3)
>3 13 (72.2) 5 (27.8) 3.4 (1.1 - 10.5)
Before age 17
0 126 (89.3) 15 (10.6) 0.06 1.0
1-2 224 (89.2) 27 (10.7) 1.2 (0.6 - 2.6)
>3 11 (68.7) 5 (31.2) 3.8 (1.1 - 12.5)
Social support (mean (95% CI))
Prenatal 14.8 (14.7 - 15.0) 13.8 (13.1 - 14.5) 0.0043 0.8 (0.7 - 0.9)
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Table 1 Associations between socio-demographic characteristics of women and their postpartum EPDS (Continued)
Postpartum 14.7 (14.5 - 14.9) 13.0 (12.2 - 13.8) 0.0001 0.8 (0.7 - 0.9)
EPDS score by time points
(mean (95% CI)
Time A (1st trimester) 4.8 (4.1 - 5.6) 8.0 (6.5 - 9.5) 0.0006 1.31 (1.11-1.55)
Time B (2nd trimester) 5.0 (4.7 - 5.4) 8.4 (7.2 - 9.5) <0.0001 1.21 (1.13-1.30)
Time C (3rd trimester) 4.5 (4.2 - 4.8) 9.0 (7.9 - 10.1) <0.0001 1.33 (1.23-1.44)
Time E (12 weeks postpartum) 3.6 (3.4 - 3.8) 12.1 (11.4 - 12.9) <0.0001 n/a
* EPDS≥10 = “at least probable minor depression”. The frequency calculations differed by variable because of missing values in some cases (e.g. participant did
not answer a question).
**Assessment of associations with Chi-square test for categorical variables or t-test for continuous variable.
***OR from univariate logistic regression.
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a woman said she consumed 700 mg/week of a nutrient, it
was calculated as 100mg/day for that specific trimester.
The daily value was calculated for the specific trimester,
and only for that trimester, and not extrapolated for the
entire pregnancy.
A trained Research Assistant conducted the interview
with each woman to elicit the information. All informa-
tion provided by the participants was reviewed with
them to ensure the items were correctly recorded.
Women were also asked to bring in bottles and other
containers of the supplements they were taking. Brand
names, individual nutrients and their amounts, as well
as dosage (i.e. number of pills/capsules/tablets taken per
day) were recorded. Prior to each visit, an email was sent
to the women, reminding them to bring in the NHP
container(s) and other materials to the next clinic visit.
When a woman did not bring in the container(s) of the
NHPs, the research assistant followed the visit with a
phone call to obtain the information.
For the purpose of this study, only supplements of
vitamins, minerals, and fatty acids were analyzed.
Supplement data was collected a minimum of two
times, and maximum of three times during preg-
nancy. To obtain an average intake of each nutrient
in the supplements, reported intake was averaged
over the number of times data were collected. For
example, if information on vitamin D supplement
intake was collected at each trimester (i.e., three
times), then the total amount consumed was divided
by three; if information was collected at only two
times, then the total was divided by two. The
nutrients chosen for analysis in this study (listed in
Table 2) were informed by the literature that has
previously demonstrated a relationship with mood
[8]. The Recommended Dietary Allowance (RDA)
values from the Institute of Medicine [35] were used
as the reference values for calculating the percentage
of women above or below RDA for consuming the
individual micronutrients from supplements. Thecomparison to RDA in this study did not include
nutrients from dietary intake, but from supplement
intake only.
Depression symptom measure – EPDS
The EPDS is a 10-item scale that measures mood, and
requires about five minutes to complete. It has been
widely validated, widely utilized, has a moderate to good
reliability and test-retest reliability and has a good to
moderate correlation with other depression measures
[36]. It has a maximum score of 30; a score of 10 or
more indicates possible depression of varying severity.
The standardized and validated EPDS has been used
extensively worldwide, and has been evaluated for its psy-
chometric rigor [37-39]. It has been found to have high
sensitivity and specificity (79% and 97% for first trimester
at cut-off of 11, 70% and 96% for second trimester with
cut-off of 10, and 76% and 94% for third trimester
with cut-off of 10 [40]) in identifying those at risk of,
or potentially suffering from prenatal depression.
The EPDS has been used for both clinical and research
purposes, and cut-off scores have been obtained through
empirical assessment [40,41]. These cut-offs provide
rates of probable depression for referral or treatment,
and can also be used to track the course of depression
from antenatal to postpartum periods. As with other
screening measures, sensitivity and positive predictive
value may be variable when used in selected populations
versus community populations [36,38]. For the purpose
of this study, we used a cut-off score of 10 for probable
depression [41]. Using the sample size of 397 we had
90% power to detect a relative risk of 1.5 or more for
EPDS >10 in women consuming lower vs. adequate
RDA of a nutrient from supplements.
Assessing predictors of depressive symptoms on the EPDS
From the first model, only born in Canada was statistically
significant (OR = 2.27, 95% CI = 1.20 - 4.31, p = 0.012). In
the second model, only postpartum social support was
statistically significant (OR = 0.83, 95% CI = 0.72 - 0.95,
Table 2 Mean (SD), range and percentage below and
above RDA for prenatal micronutrient intake from
supplementation in pregnant women with postpartum
EPDS<10 & EPDS≥10
Nutrient EPDS<10 EPDS≥10 p-value*
(n=416) (n=59)
Vitamin B1 (mg)
Mean (SD) 5.5 (14.7) 3.5 (8.1) 0.12
Range 0 – 103 0 – 62.5
Below RDA (n (%)) 55 (84.6) 10 (15.4)
Above RDA (n (%)) 361 (88.1) 49 (11.9)
Vitamin B3 (mg)
Mean (SD) 22 (23) 19 (10) 0.10
Range 0 – 335 0 – 66
Below RDA (n (%)) 55 (82.1) 12 (17.9)
Above RDA (n (%)) 361 (88.5) 47 (11.5)
Vitamin B6 (mg)
Mean (SD) 9.1 (15.9) 7.8 (10.7) 0.43
Range 0 – 110 0 – 62.5
Below RDA (n (%)) 23 (79.3) 6 (20.7)
Above RDA (n (%)) 363 (88.1) 49 (11.9)
Vitamin B9 (mcg)
Mean (SD) 1259 (924) 1297 (962) 0.78
Range 0 – 6000 0 – 5000
Below RDA (n (%)) 30 (81.1) 7 (18.9)
Above RDA (n (%)) 386 (88.1) 52 (11.9)
Vitamin B12 (mcg)
Mean (SD) 31 (116) 18 (65) 0.23
Range 0 – 1210 0 – 502
Below RDA (n (%)) 19 (79.2) 5 (20.8)
Above RDA (n (%)) 397 (88.0) 54 (12.0)
Vitamin D (IU)
Mean (SD) 618 (539) 567 (512) 0.48
Range 0 – 4200 0 – 2750
Below RDA (n (%)) 292 (87.7) 41 (12.3)
Above RDA (n (%)) 124 (87.3) 18 (12.7)
Iodine (mcg)
Mean (SD) 173 (68) 158 (76) 0.15
Range 0 – 636 0 – 330
Below RDA (n (%)) 227 (85.7) 38 (14.3)
Above RDA (n (%)) 189 (90.0) 21 (10.0)
Iron (mg)
Mean (SD) 33 (20) 32 (20) 0.84
Range 0 – 127 0 – 87
Below RDA (n (%)) 68 (82.9) 14 (17.1)
Above RDA (n (%)) 348 (88.5) 45 (11.5)
Table 2 Mean (SD), range and percentage below and
above RDA for prenatal micronutrient intake from
supplementation in pregnant women with postpartum
EPDS<10 & EPDS≥10 (Continued)
Magnesium (mg)
Mean (SD) 67 (65) 59 (39) 0.19
Range 0 – 1025 0 – 208
Below RDA (n (%)) 415 (87.5) 59 (12.5)
Above RDA (n (%)) 1 (100.0) 0
Selenium (mcg)
Mean (SD) 25 (17) 19 (13) 0.0015
Range 0 – 125 0 – 45
Below RDA (n (%)) 401 (87.2) 59 (12.8)
Above RDA (n (%)) 15 (100.0) 0
Zinc (mg)
Mean (SD) 13 (8) 12 (8) 0.38
Range 0 – 48 0 – 32
Below RDA (n (%)) 233 (87.9) 32 (12.1)
Above RDA (n (%)) 183 (87.1) 27 (12.9)
Omega-3 (mg)
Mean (SD) 180 (440) 90 (208) 0.01
Range 0 – 4050 0 – 1000




Above RDA (n (%))
Note: RDA (Recommended Dietary Allowance) for pregnant women is “the
average daily nutrient intake level sufficient to meet the nutrient requirement
of nearly all (97– 98%) healthy individuals in a particular life stage and gender
group” as defined by the Institute of Medicine (55). The percentages below
and above RDA are calculated from supplements alone and does not account
for dietary intake.
SD = Standard deviation.
* p values derived from t-tests.
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resulted in only selenium being statistically significant
(OR = 0.97, 95% CI = 0.94 - 0.99, p = 0.030).
Although omega-3 was not significant in the logistic
regression (OR = 1.00, 95% CI = 0.99 - 1.00, p = 0.07),
given the strong association of omega-3 with depressive
symptoms, both selenium and omega-3 were included in
the next model with the significant variables from the first
two models.
The fourth model was constructed to include born in
Canada, prenatal and postnatal social support, prenatal
EPDS (at 2nd and 3rd trimesters) and prenatal omega-3
and selenium supplement. Prenatal EPDS scores were
included because the literature has reported that pre-
natal depressive symptoms were predictive of post-
partum depressive symptoms. Born in Canada, prenatal
social support, and omega-3 were removed from the
fourth model as they exceeded the pre-set p value of
0.05. Potential confounding of the remaining model by
sociodemographic and lifestyle variables was assessed.
Table 3 Full and final models of predictors for EPDS
depressive symptoms (EPDS≥10)
Predictor Odds ratio 95% CI p-value
Model 1
Age .98 .88-1.09 .69
Parity .98 .56-1.71 .94
Marital status .49 .19-1.24 .14
Education .98 .63-1.51 .92
Income 5.32 .85-33.35 .07
Born outside Canada 2.41 .81-7.19 .11
Ethnic background .73 .19-2.79 .65
BMI 1.00 .88-1.15 .90
Model 2
Life stressors during this pregnancy 1.21 .87-1.69 .26
Life stressors 12 mons before this
pregnancy
1.08 .77-1.50 .65
Life stressors prior to age 17 1.22 .85-1.75 .29
Social support .85 .74-.97 .015
Model 3
Vitamin B1 .98 .94-1.02 .33
Vitamin B3 .99 .97-1.01 .41
Vitamin B6 1.01 .98-1.05 .41
Vitamin B9 (folic acid) 1.00 .99-1.00 .96
Vitamin B12 1.00 .99-1.00 .76
Vitamin D 1.00 .99-1.00 .92
Iodine .99 .99-1.00 .11
Iron 1.00 .98-1.01 .91
Magnesium .99 .99-1.00 .37
Selenium .97 .95-0.99 .03
Zinc .98 .95-1.02 .41
Omega 3 1.00 .99-1.00 .20
Final model
Prenatal EPDS (2nd trimester) 3.29 1.55 – 7.01 0.004
Prenatal EPDS (3rd trimester) 4.26 2.05 – 8.85 0.000
Postpartum Social Support 0.87 0.78 - 0.97 0.015
Prenatal Selenium supplement
intake (per 10 mcg)
0.76 0.74 - 0.78 0.019
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crude and adjusted ORs. Therefore, the final model
consisted of predictors that were statistically significant
(see Table 3). Hosmer and Lemeshow's goodness-of-fit test
resulted in chi2(7) = 8.08, and p = 0.33, indicating that our
model fits the data well. The mean VIF = 1.13, with VIF for
individual variable ranged from 1.03 to 1.17 (and tolerance
from .84 to .97), indicating that multicollinearity is not
likely to be a problem in the model.
Missing values
To assess whether the 125 “missing” postpartum EDPS
participants differed from those who responded, various
statistical tests were used, including 1) exclusion of cases
with missing postpartum EPDS, 2) re-categorization of
missing as “not depressed”, 3) re-categorization of missing
as “depressed”, 4) last observation carried forward using
third trimester data, 5) creation of a category called
“missing” to see what predicted “missing”, and 6) compari-
son of participant characteristics with those without
postpartum EPDS data.
Statistical methods
All statistical analyses were performed using STATA11
software. Values were expressed as mean and standard
deviation, range, or proportions (n and %). Comparisons
between groups (those having EPDS scores <10 and those
with EPDS scores ≥10) were assessed for statistical signifi-
cance by a Chi-square test for categorical variables and a
t-test for continuous variables. Bonferroni correction was
used for multiple test comparisons. Several logistic regres-
sion models were constructed to identify predictors of
postpartum depression. Using multivariate logistic regres-
sion, the first model consisted of all the demographic
variables; model two included social/lifestyle variables plus
the significant variable from model one. The third model
assessed nutrients from supplement intake (listed in
Table 2), and the fourth model incorporated significant
(and close to significant) variables from models one, two,
and three (all the models with the covariates and nutrients
and their respective outputs are provided in Table 3). For
the final model, we tested the fit of the model with
Hosmer and Lemeshow's goodness-of-fit test, and we
computed the variance inflation factor (VIF) to test for
collinearity. Odds ratios (OR) and the 95% CI for
predictors of the EPDS depressive symptoms were
calculated. A two-tailed p-value of 0.05 was considered
statistically significant.
Ethics approval
The APrON study was approved by the Conjoint Health
Research Ethics Board at the University of Calgary, and
the Health Research Ethics Board at the University ofAlberta. Each participant signed a consent form at the
first clinic visit.
Results
Of the 600 pregnant women in the study cohort, 475
completed the EPDS questionnaire at least twice during
pregnancy and at 12 weeks postpartum. Of the 125 with
no EPDS data postpartum, nine miscarried, 36 withdrew
from the study, 38 were non-respondent (i.e., could not
be contacted), and 36 did not complete the EPDS. No
differences in characteristics were found between those
with postpartum EDPS data and those without.
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on the EPDS and 59 (12%) scored ≥10. For demographic
characteristics, women not born in Canada were more
likely to have an EPDS ≥10 (p = 0.01); no other potential
covariates were statistically significant (see Table 1). For
the social/lifestyle characteristics, the number of chronic
conditions, stressful life events during this pregnancy, and
pre/post-natal support were all statistically significant
(see Table 1); i.e. EPDS was associated with these
characteristics. Women with higher number of stress-
ful life events 12 months before pregnancy and before
the age of 17 were more likely to have EPDS ≥10,
with p-values close to significance (p = 0.08 and 0.06
respectively). Not presented were regressions for
prenatal depression and the key nutrients found to be
significantly associated with postpartum depression:
the results (not shown) were that selenium was not a
predictor of prenatal depression at second or third
trimesters. Although not statistically significant, a
trend was shown for women being single/divorced,
had lower income, or had higher number of children
to be associated with EPDS ≥10.
Nutrient data
Almost all women (99%) took some type of micronu-
trient supplement during the prenatal period. For this
cohort, the nutrients most commonly consumed were
vitamins B6, B9 (folate), B12, and E, with more than 90%
above RDA. The supplement taken the least was omega-3,
where 68.5% of women with EPDS <10 and 78.0% of
women with EPDS ≥10 did not take any omega-3. The
mean intake of selenium and omega-3 differed significantly
(p = 0.0015 and 0.01, respectively) between women with
EPDS <10 and those with EPDS ≥10. As well, the mean
intakes for all the other nutrients listed in Table 2 were
more likely to be higher in women with EPDS <10 than
those with EPDS ≥10, although not statistically significant.
In fact, the upper ranges for intake were higher in almost
all nutrients (except for folic acid) in women with
EPDS <10 than women with EDPS ≥10. Finally, all
the other nutrients listed (except vitamin D and zinc)
showed an overall nonsignificant trend for those con-
suming below RDA levels to be more likely to have
EPDS ≥10 (see Table 2). Supplement intake for many
of the nutrients was not normally distributed. SIQ
data was available for n=136 in the first trimester,
n=575 in the second trimester and n=516 in the
third trimester.
Table 3 showed the (statistically significant) predictors
for postpartum depressive symptoms (i.e. EPDS ≥10)
from the final model. Selenium use above RDA levels
and postnatal social support reduced the odds of the
EPDS ≥10, while prenatal EPDS (at 2nd and 3rd
trimesters) increased the risk of EPDS ≥10.Discussion
The results of this research support previous studies on
the nutritional and social factors associated with depres-
sion [5,42,43]. In this study, women with an EPDS score
≥10 were more likely to be born outside of Canada; to
report having more chronic health conditions, more life
stress and less social support during the current
pregnancy; and to have consumed fewer micronutrients
from supplements, most notably selenium and omega-3.
The logistic regression showed that prenatal EPDS ≥10
(at second and third trimesters) increased the odds of
postpartum depressive symptoms, while prenatal selen-
ium intake from supplements and postnatal social
support were protective (decreased the odds) of postpartum
depressive symptoms. Of the nutrients evaluated, all intakes
were likely to be higher in women with EPDS <10 than
those with EPDS ≥10.
The role of selenium in relation to mood is not as well
studied as some other nutrients (e.g. omega-3s, folate, and
zinc) that have been associated with depression. A recent
nested case–control study by Pasco and colleagues found
low intake of selenium (<8.9 μg/MJ/day) was associated
with almost a three-fold increase in the likelihood of major
depressive disorder (OR 2.95, 95% CI 1.00-8.72) after
adjusting for age and socio-economic status [44]. A
randomized trial by Mokhber and colleagues reported
significantly lower mean EPDS scores in the group of
primigravid pregnant Iranian women, aged 16 to 35, taking
selenium supplements compared to a comparison group
after controlling for sociodemographic and health history
variables [42]. Hawkes and Hornbostel in a study of eleven
healthy men found lower selenium status associated with
worse mood scores [45].
This study reinforced the importance of social support
for pregnant women in the prenatal and postnatal periods,
the benefits of which have been well-documented for the
reduction of the risk and symptoms of mood disorders
and depression [43,46,47]. While there is little research
into the mechanism by which environmental factors such
as social support affect brain biochemistry in humans,
animal studies indicate that improving external stimuli
through an enriched environment may reverse the effects
of stress-related events, at the behavioral, endocrine, and
biochemical levels [48].
The findings from this study also revealed the need for
evaluation for prenatal depressive symptoms. While
there are programs in many jurisdictions to evaluate
new mothers for the risk of this condition, prenatal
mental health still receives little attention as part of pre-
natal care [49,50]. Since antenatal depression may be more
common than postnatal depression, and women with
antenatal depression are more likely to be depressed
postnatally [51], prenatal depression screening should be
as widely practiced as postpartum screening.
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collinearity, which is a common problem in nutrition
studies, particularly those that examine the intake of
nutrients from supplements as supplements include mul-
tiple nutrients and many are in similar amounts and
combinations due the nutrient recommendations by health
agencies. Another limitation is that the present study did
not have access to serum levels of selenium or any of the
other nutrients discussed in this paper, thus there is no in-
formation as to whether supplementation affected bio-
logical levels. A third limitation was that dietary (food)
intake was not included in the analysis. Although dietary
intake was estimated in these women at two or three
trimesters during pregnancy (data which will be available at
some future date), selenium intake is difficult to estimate
due to variations in the food supply and the inaccuracy of
nutrient databases. The high supplement intake may miti-
gate dietary intake in this case, and would not be likely to
change our findings. We did not have lab values at present
to assess anemia in our sample. Although anemia is known
to be a risk factor for depression, we also know that women
are routinely supplemented with iron when anemia is
diagnosed during pregnancy. In this study, for women
below RDA, 82.9% scored <10 EPDS, 17.1% scored ≥10
EPDS; for women above RDA, 88.5% <10 EPDS, and 11.5%
were ≥10, p = 0.84 (see Table 2), indicating that there was
no difference of scoring ≥10 EPDS between being above or
below the RDA for iron. While we recognize this is not the
ideal measure for iron associated form of anemia, it served
as a proxy for iron status. Another limitation was possible
reporting error associated with recall of supplement intake
(e.g. dosage and frequency). Recording of brand names and
labels of supplements (e.g. types and amounts of nutrients)
by research assistants, as well as the use of repeated
measures, helped to minimized potential reporting bias.
However, we acknowledge a major limitation with the Sup-
plement Intake Questionnaire is self-reporting; thus we did
not know whether the women actually consumed their
supplements as they said they did. Furthermore, if a woman
missed her trimester visit then this was treated as missing
data and no estimation was made. Thus, there was some
degree of projection as the women were asked for informa-
tion for the entire trimester at the trimester midpoint and
not the end, making this a limitation to our estimates. A
limitation in the analysis was that we did not assess for
interaction among the nutrients due to the absence of any
a priori rationale from the literature. In addition, as data on
prenatal nutrition status was not available, we were
unable to test whether the effect of prenatal micronu-
trient supplementation on postpartum depression
varied by prenatal nutritional status. For future
research, we would like to assess whether specific
nutrients interact to impact postpartum depression,
and also whether prenatal nutritional status modifiedthe association of supplementation and postpartum
depression.
One of the strengths of this study was the temporal re-
lationship of supplement intake and postpartum depres-
sive symptoms could be established. Another strength
was that supplement intake was collected repeatedly
over time to obtain an average usual intake of the
nutrients in the prenatal period, rather than using a sin-
gle measure as in most studies. A third strength was the
ability to control for a large number of factors associated
with postpartum depressive symptoms in our analyses
because of the variables (demographic, social, lifestyle)
collected prospectively.
Implications for future research include examining
objective measures of pre- and postnatal micronutrient sta-
tus for: 1) relations between pre/postnatal blood nutrient
levels (or changes in pre/postnatal blood levels) and
postpartum depression, 2) moderating effect of prenatal
blood nutrient levels on the relations between prenatal
micronutrient supplementation and postpartum depres-
sion, and 3) interactions amongst nutrients and their
effects on postpartum depression.
Conclusions
This study found multiple factors, including selenium
intake from supplements, history of depression, and social
support, are associated with the risk of postpartum depres-
sive symptoms. The evidence suggests that there is likely
no single casual factor to depression, and nutrients play an
important role in the development of depressive symptoms.
Thus, a future research focus on dietary supplementation
with special attention to the intake of selenium in the
pregnant population is warranted.
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